MX2021010987A - Composicion farmaceutica para el tratamiento contra aneurisma aortico. - Google Patents
Composicion farmaceutica para el tratamiento contra aneurisma aortico.Info
- Publication number
- MX2021010987A MX2021010987A MX2021010987A MX2021010987A MX2021010987A MX 2021010987 A MX2021010987 A MX 2021010987A MX 2021010987 A MX2021010987 A MX 2021010987A MX 2021010987 A MX2021010987 A MX 2021010987A MX 2021010987 A MX2021010987 A MX 2021010987A
- Authority
- MX
- Mexico
- Prior art keywords
- aortic aneurysm
- therapeutic agent
- pharmaceutical composition
- treating aortic
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención aborda el problema de proporcionar un agente terapéutico contra un aneurisma aórtico abdominal, en donde el agente terapéutico hace posible la terapia farmacológica. La presente invención proporciona un agente terapéutico contra el aneurisma aórtico, en donde el agente terapéutico tiene como principios activos: (-)-6-[3-[3-ciclopropil -3-[(1R,2R)-2-hidroxiciclohexil]ureido]propoxi]-2(1H)-quinolinona o una sal de la misma, o un solvato de la misma; y una estatina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019045333 | 2019-03-13 | ||
PCT/JP2020/011042 WO2020184703A1 (ja) | 2019-03-13 | 2020-03-13 | 大動脈瘤の治療用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010987A true MX2021010987A (es) | 2021-12-15 |
Family
ID=72427139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010987A MX2021010987A (es) | 2019-03-13 | 2020-03-13 | Composicion farmaceutica para el tratamiento contra aneurisma aortico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220184058A1 (es) |
EP (1) | EP3939656A4 (es) |
JP (1) | JPWO2020184703A1 (es) |
KR (1) | KR20210144657A (es) |
CN (1) | CN113316469A (es) |
BR (1) | BR112021018017A2 (es) |
CA (1) | CA3133209A1 (es) |
MX (1) | MX2021010987A (es) |
SG (1) | SG11202109928WA (es) |
TW (1) | TW202100155A (es) |
WO (1) | WO2020184703A1 (es) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
JPS572240A (en) | 1980-06-06 | 1982-01-07 | Sankyo Co Ltd | Ml-236b derivative |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
PH23486A (en) | 1982-11-22 | 1989-08-16 | Sanzoz Inc | Indole analogs of mevalonolactone,pharmaceutical compositions containing the same and method of use thereof |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
TW338037B (en) | 1995-10-05 | 1998-08-11 | Otsuka Pharma Co Ltd | Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition |
WO2006132091A1 (ja) * | 2005-06-08 | 2006-12-14 | Kowa Company, Ltd. | 新規なトリグリセリド低下剤 |
JP2007230884A (ja) * | 2006-02-28 | 2007-09-13 | Kowa Co | 脊柱管狭窄症の予防及び/又は治療剤 |
WO2013103148A1 (ja) * | 2012-01-05 | 2013-07-11 | 興和株式会社 | 側副血行路発達促進剤 |
JP6367581B2 (ja) * | 2014-03-18 | 2018-08-01 | 国立大学法人浜松医科大学 | 動脈瘤縮小剤 |
-
2020
- 2020-03-13 CA CA3133209A patent/CA3133209A1/en active Pending
- 2020-03-13 CN CN202080009881.7A patent/CN113316469A/zh active Pending
- 2020-03-13 MX MX2021010987A patent/MX2021010987A/es unknown
- 2020-03-13 WO PCT/JP2020/011042 patent/WO2020184703A1/ja unknown
- 2020-03-13 TW TW109108402A patent/TW202100155A/zh unknown
- 2020-03-13 KR KR1020217019386A patent/KR20210144657A/ko unknown
- 2020-03-13 US US17/438,309 patent/US20220184058A1/en active Pending
- 2020-03-13 EP EP20770836.3A patent/EP3939656A4/en active Pending
- 2020-03-13 JP JP2021505156A patent/JPWO2020184703A1/ja active Pending
- 2020-03-13 SG SG11202109928W patent/SG11202109928WA/en unknown
- 2020-03-13 BR BR112021018017A patent/BR112021018017A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
US20220184058A1 (en) | 2022-06-16 |
JPWO2020184703A1 (es) | 2020-09-17 |
CN113316469A (zh) | 2021-08-27 |
EP3939656A1 (en) | 2022-01-19 |
TW202100155A (zh) | 2021-01-01 |
EP3939656A4 (en) | 2022-12-07 |
KR20210144657A (ko) | 2021-11-30 |
BR112021018017A2 (pt) | 2021-11-23 |
SG11202109928WA (en) | 2021-10-28 |
WO2020184703A1 (ja) | 2020-09-17 |
CA3133209A1 (en) | 2020-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20190186A1 (ar) | مركب كينازولين | |
MA41496B1 (fr) | Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
MX2023009521A (es) | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d. | |
MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
MX2019012884A (es) | Terapia de combinacion. | |
EA202191361A1 (ru) | Способы лечения муковисцидоза | |
SG11201912110YA (en) | Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient | |
MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
BR112017020948A2 (pt) | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão | |
PH12017500436A1 (en) | Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence | |
IL291168A (en) | A result of heteroarylamidopyridinol and a pharmaceutical preparation containing it as an active ingredient for the prevention or treatment of autoimmune disease | |
MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
EP3541943A4 (en) | MICRO-ORGANISM FOR ADMINISTERING A MEDICINAL PRODUCT FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE, WHICH EXPRESSES AND SECRETS P8 PROTEIN, AND PHARMACEUTICAL COMPOSITION CONSISTING OF THIS MICRO-ORGANISM FOR THE PREVENTION OR TREATMENT OF A GASTROINTESTINAL DISEASE | |
EA202290154A1 (ru) | Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты | |
MX2022010748A (es) | Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1). | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
MX2023009723A (es) | Inhibidores de tyk2 y sus usos. | |
MX2022004027A (es) | Farmaco farmaceutico que contiene derivado de heterocicliden acetamida. | |
EP4003332A4 (en) | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND ITS USE FOR PREVENTING AND/OR TREATING A DISEASE | |
MX2021010987A (es) | Composicion farmaceutica para el tratamiento contra aneurisma aortico. | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
PH12019502580A1 (en) | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio | |
IL307997A (en) | Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases | |
MX2018000963A (es) | Composicion farmaceutica sinergica del enantiomero activo s-ketorolaco trometamina y clorhidrato de tramadol. |